Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for coronary microvascular dysfunction in women with angina and no obstructive coronary stenosis
2015-002153-35Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of liraglutide in microvascular angina (MVA), Coronary Small Vessel Disease (CMD) and angina pectoris, sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Change in coronary flow reserve. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
microvascular angina (MVA)Coronary Small Vessel Disease (CMD)angina pectoris
Beyond the preview
Go deeper on 2015-002153-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002153-35.